Bon Natural Life Limited

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.

Bon Natural Life Limited trades as BON on NASDAQ. The company is classified in Consumer Defensive / Packaged Foods and reports in USD.

The current profile places the business in Packaged Foods. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $18.67M of revenue and -$1.99M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Bon Natural Life Limited can be compared against peers such as Amaze Holdings, Inc., Edible Garden AG Incorporated, Healthy Choice Wellness Corp., IP Strategy Holdings, Inc., Maison Solutions Inc. Class A Common Stock, Natural Alternatives International, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $7.61M, beta of -0.17, and return on equity of -3.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BON currently shows total debt of $12.32M and beta of -0.17. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 3 (2026-05-15 00:00:00), 3 (2026-04-23 00:00:00), 3 (2026-04-10 00:00:00), 3 (2026-04-10 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.bnlus.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.